The Effect of Short-term Dutasteride Intake in Early-stage Prostate Cancer: Analysis of 148 Patients Who Underwent Three-dimensional Prostate Mapping Biopsy

Barqawi, Al B.; O’Donnell, Colin; Siomos, Vassilis J.; Hou, Amy

doi:10.1016/j.urology.2010.02.063

Cited by 11 publications

(5 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Increasing evidence suggest that enhanced intratumoral androgen synthesis may be one cause of resistance to androgen deprivation therapy. A recent study indicated that men who underwent transperineal three‐dimensional mapping (TP‐3DM) biopsy of the prostate and received dutasteride treatment for at least 3 months before biopsy showed ∼24% decrease in the upstaging and/or upgrading of prostate cancer compared to the control group that did not receive dutasteride 21, demonstrating a potential role for dutasteride in tertiary chemoprevention. Another large‐scale clinical trial showed that dutasteride reduced the risk of incident prostate cancer detected on biopsy and improved the outcomes related to benign prostatic hyperplasia 22.…”

Section: Discussionmentioning

confidence: 99%

Role of dutasteride in pre‐clinical ETS fusion‐positive prostate cancer models

et al. 2012

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Role of dutasteride in pre‐clinical ETS fusion‐positive prostate cancer models

et al. 2012

View full text Add to dashboard Cite

show abstract

“…and P.D.M.). We have previously described the TPMB biopsy technique that was performed in this study [16]. Briefly, TPMB was done as a day surgery procedure under conscious sedation in the operative suite.…”

Section: Patient Selectionmentioning

confidence: 99%

Clinical‐Pathologic Correlation Between Transperineal Mapping Biopsies of the Prostate and Three‐Dimensional Reconstruction of Prostatectomy Specimens

et al. 2012

Self Cite

View full text Add to dashboard Cite

Background Extended transrectal ultrasound guided biopsies (TRUSB) of the prostate may not accurately convey true morphometric information and Gleason score (GS) of prostate cancer (PCa) and the clinical use of template-guided (5-mm grid) transperineal mapping biopsies (TPMBs) remains controversial. Methods We correlated the clinical-pathologic results of 1,403 TPMB cores obtained from 25 men diagnosed with PCa with 64 cancer lesions found in their corresponding radical prostatectomy (RP) specimens. Special computer models of three-dimensional, whole-mounted radical prostatectomy (3D-WMRP) specimens were generated and used as gold standard to determine tumor morphometric data. Between-sample rates of upgrade and downgrade (highest GS and a novel cumulative GS) and upstage and downstage (laterality) were determined. Lesions ≥ 0.5 cm3 or GS ≥ 7 were considered clinically significant. Results From 64 separate 3D-WMRP lesions, 25 had significant volume (mean 1.13 cm3) and 39 were insignificant (mean 0.09 cm3) (P < 0.0001); 18/64 lesions were missed by TPMB, but only one was clinically significant with GS-8 (0.02 cm3). When comparing the cumulative GS of TPMB versus RP, 72% (n = 18) had identical scores, 12% (n = 3) were upgraded, and only 16% (n = 4) were downgraded. Laterality of TPMB and RP was strongly correlated, 80% same laterality, 4% were up-staged, and 16% down-staged. Conclusions Our clinical-pathology correlation showed very high accuracy of TPMB with a 5-mm grid template to detect clinically significant PCa lesions as compared with 3D-WMRP, providing physicians and patients with a reliable assessment of grade and stage of disease and the opportunity to choose the most appropriate therapeutic options.

show abstract

“…It is 60 times more potent than finasteride, is well tolerated and has been shown to significantly reduce serum and intraprostatic DHT in BPH and prostate cancer patients [18][19][20]. It was also found to significantly decrease tumor volume in patients and was found to delay incidence of prostate cancer in high risk individuals as well as progression of prostate cancer development [20][21][22][23]. However, it is not typically the drug of choice as a first line hormonal treatment for prostate cancer [24][25][26].…”

Section: Introductionmentioning

confidence: 99%